Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Lamivudine treatment for chronic hepatitis B infection

Children with chronic hepatitis B infection treated with lamivudine, following failure of interferon therapy, show decreased HBV replication and improved ALT values, find researchers in the March issue of the Pediatric Infectious Diseases Journal.

News image

Lamivudine is a potent inhibitor of hepatitis B virus (HBV) replication.

In this study, researchers from Israel assessed the results of lamivudine treatment in children with chronic hepatitis B infection who did not respond to interferon treatment.

Lamivudine (3 mg/kg/day) was given to 20 children and adolescents (aged 8 to 19 years) with chronic hepatitis B, for a period of 52 weeks. The children had previously been treated with interferon, between 2 and 5 years earlier.

The researchers evaluated virologic and biochemical responses, the occurrence of YMDD mutants, and adverse effects.

At the end of 1 year, HBV DNA declined by 95% in all patients.
Pediatric Infectious Diseases Journal

The team found that all children were HBV DNA+, hepatitis B e antigen (HBeAg)+/anti-hepatitis B e antibody- at start of treatment.

At the end of 1 year, HBV DNA declined by 95% in all patients, and 44% had sustained undetectable HBV DNA by hybridization assay.

In addition, median pretreatment alanine aminotransferase (ALT) x 1.5 upper limit of normal, decreased to ALT x 0.9 upper limit of normal after 1 year.

Of the 20 children, 1 became HBeAg-negative.

However, the team detected YMDD mutants in 65% of children after 1 year of lamivudine treatment.

Among children with YMDD mutant variants, 54% maintained normal ALT values and 45% had undetectable HBV DNA by hybridization assay.

No adverse effects were observed.

Dr Corina Hartman's team concluded, "Children with chronic hepatitis B infection treated with lamivudine after failure of interferon therapy had decreased HBV replication and improved ALT values".

"However, lamivudine treatment resulted in an exceptionally high rate of lamivudine-resistant mutants and low HBeAg seroconversion rate."

Pediatr Infect Dis J 2003; 22(3): 224-9
14 March 2003

Go to top of page Email this page Email this page to a colleague

 04 March 2015

Advanced search
 04 March 2015 
Progression of Barrett's
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Management of IBD
 03 March 2015 
Risk of anastomotic leak after colectomy
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 02 March 2015 
Liver disease in patients awaiting liver transplant
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Prevalence of microscopic colitis
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patientsí colonoscopist selection
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
NAFLD and CVD
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization
 05 February 2015 
GERD, dyspepsia and IBS symptoms
 05 February 2015 
Thalidomide and refractory Crohn's
 05 February 2015 
Quality of life in Crohn's after antitumor necrosis factor agents

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us